Description

With an overall 5-year survival of only 20% for advanced stage ovarian cancer (OC) patients, OC is a high unmet clinical need. Targeted therapies were able to improve progression free survival, though patients still relapse. On top, immunotherapy has so far not resulted in clear patient benefit. Importantly, the role of dendritic cells (DCs) as a key player in mounting an adaptive immune response has not been investigated yet in OC. Moreover, our lab has uncovered that vaccination with tumor-cDCs can elicit a therapeutically relevant immune response resulting in decreased tumor growth. Therefore, in this PhD project, we will evaluate the cDC heterogeneity in OC and the potential to use tumorcDCs as vaccine to treat OC. More specifically, we will identify and characterize different cDC populations at the transcriptomic, proteomic and functional level in both a murine OC model and patient samples using state-of-theart technologies. Reflecting the current treatment of OC patients, we will also investigate the impact of standard of care chemotherapeutics on tumor-cDC function and assess the role of immunosuppressive cells thereon. As last, in the murine OC model, we will determine the effectiveness of the different cDC populations as OC vaccine. The results of this project will provide new insights into the role of cDCs in OC and will propose a novel therapeutic approach for OC that overcomes the currently witnessed barriers to effective therapeutic responses.
AcronymANI258
StatusNot started
Effective start/end date1/11/2031/10/21

    Flemish discipline codes

  • Other medical and health sciences not elsewhere classified

    Research areas

  • ovarian cancer

ID: 53755044